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The GABRB3 gene is a recently identified gene in a locus known with various clusters of major genes in the long arm of chromosome 15.1 This 
15q11-q13 locus is a known region of different 
genomic DNA deletions and duplications related to 
some neurodegenerative and neurodevelopmental 
disorders including , for example, Angelman 
syndrome and autism spectrum disorder (ASD).2,3 
Several gamma-aminobutyric acid (GABA) genes 
are mapped to the nearby 15q12 locus.4 It is believed 
that any changes in the GABAergic signaling 
pathway are likely to result in several neurological 
disorders. However, the spectrum and extension of 
such clinical implications are yet to be unraveled. 
Our three reported cases do illustrate the likely wide 
variation in clinical phenotype in heterozygous 
GABRB3 mutations.
C A S E  R E P O RT
Case one
A previously healthy male infant was thought to 
have a normal neurodevelopmental profile till 
the age of 20-month-old at presentation. He was 
born at term after an uneventful pregnancy and 
uncomplicated normal delivery. His family history 
was negative for any neurological or developmental 
disorders in close blood relatives. He was noted to 
have several worrisome observations around the 
age of 20 months old, including progressive loss of 
consistent eye contact, consistently irritable mood 
with inconsolable high pitch cry, and worsening 
loss of prior vocabulary and speech abilities. He was 
described as more clumsy and noted to have more 
frequent falling than usual as he started walking 
around the age of one-year-old. Multiple family 
members noticed overall worsening with decreased 
interaction with family members and usual 
social cues. Because of the numerous concerning 
observations, his primary care physician initiated an 
urgent referral to the neurology specialist service. 
Upon evaluation by neurology service, he was found 
to be well-looking with no signs of acute illness. 
However, he had multiple abnormal neurological 
exam findings such as poor eye contact, irritable 
mood, diffusely decreased axial and appendicular 
tone, along with brisk deep tendon reflexes 
throughout all extremities. No nystagmus, cranial 
nerve palsies, striking abnormal facial features, 
or neurocutaneous signs were noted. No joint 
contractures or deformities were found. With this 
concerning neurological decline and abnormal 
physical exam, a brain magnetic resonance imaging 
(MRI) with magnetic resonance spectroscopy was 
completed and interpreted as an unremarkable study. 
Basic and targeted metabolic screening was obtained, 
including lysosomal, thyroid, amino acid, fatty acid, 
and immune disorders, which were all found to be 
negative. DNA genomic micro-array sequencing 
test was then done and showed heterogeneous de 
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A B S T R AC T
GABRB3 gene is a recently identified gene located in 15q12 chromosome and encodes 
for gamma-aminobutyric acid (GABA) receptor subunit beta-3 protein, which is linked 
to the GABAA receptor. The gene is believed to share a role in inhibitory GABAergic 
synapses, GABA iron-gated channel function, and possible cellular response to 
histamine. The β3 subunit is expressed in cerebral grey matter, thalami, hippocampi, 
and cerebellum, among other structures. Faulty GABRB3 function is linked to several 
neurological disorders and clinical syndromes. However, the spectrum of such disorders 
is not yet well known. We present three case reports highlighting the potentially 
expanding clinical phenotype and variable expression in children with mutated 
GABRB3 gene.
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novo p.l3101 pathogenic variant of GABRB3. 
Although his variant was not previously reported, it 
was thought to be pathological and likely represents 
the underlying etiology of his clinical symptoms 
and signs. The patient was started on an intensive 
rehabilitation program. Interestingly, his response to 
physical, occupational, and speech therapy services 
were positive and remarkable, and he continues to 
make developmental progress.
Case two
An 18-month-old female infant presented to the 
emergency department for the first time with 
likely a brief febrile seizure. She was a product 
of an uneventful pregnancy, regular reassuring 
prenatal care, and spontaneous vaginal delivery at 
38 weeks estimated gestational age. She attained 
all her motor and social developmental milestones 
within the normal range expected timelines with no 
regression. However, she was observed to have mild 
expressive speech delay as she was able to only say 
five to six words at the age of 18 months and could 
not combine words. Her family history included a 
cousin with childhood-onset epilepsy and another 
cousin with febrile seizures. Upon presentation to 
the emergency room, she had an apparent focal onset 
for her seizure with lateralized versive eye gazing, 
focal unilateral facial twitching, and unilateral 
body shaking. She was febrile with some upper 
respiratory symptoms but no other symptoms or 
signs of serious or central nervous system infection. 
Her exam was reassuring after recovering from the 
postictal period, and no focal neurological signs 
were elicited. extensive infectious workup was 
negative. During hospitalization, she had two more 
similar seizures. Because of seizure recurrence and 
onset focality, she was ultimately diagnosed with a 
complex febrile seizure. She was temporarily started 
on levetiracetam because of seizure recurrence with 
anticipation of the need for only short-term course. 
Her electroencephalogram (eeG) study was normal. 
Her brain MRI demonstrated a borderline chiari 
1 malformation but was otherwise unremarkable 
and showed no evidence of hippocampal sclerosis 
or focal cortical dysplasia. Given the mild speech 
delay background, atypical clinical course for 
febrile seizures, and family history, genetic testing 
was then considered. chromosome microarray 
revealed p.P54l heterozygous autosomal dominant 
pathogenic variant of GABRB3.  A diagnosis of 
generalized epilepsy with febrile seizures plus 
(GeFS+) was determined. Her seizures were well-
controlled with levetiracetam and medication 
weaning is planned.
Case three
This male patient was born full-term (40 
weeks estimated gestational age) after a largely 
uncomplicated pregnancy and delivery with no 
neonatal resuscitation or critical care needs. He had 
normal behavioral and developmental progress up to 
near puberty age, and no major health comorbidities 
were noted. With a rather acute history, he 
presented at the age of 12 years old with an acute 
mental status change in the form of sudden onset of 
repeating certain phrases inappropriately outside the 
situational context. Other interesting behaviors were 
also observed, such as continuous scribbling and 
walking around in circles. Mental state examination 
revealed deficits in short-term memory and abstract 
thinking. However, physical and neurological exams 
were otherwise unremarkable. He was diagnosed 
preliminarily with acute encephalopathy. complete 
blood count, chemistry profile, drug screening, and 
basic metabolic profile were all within normal limits. 
Head computed tomography scan was normal. As 
a part of medical evaluation, eeG was requested 
and showed near continuous spike and slow-wave 
complexes consistent with non-convulsive status 
epilepticus. Anti-seizure medications were initiated, 
and he showed a good initial response to the 
benzodiazepine trial with lorazepam and midazolam. 
However, his seizures were difficult to control over 
time, so detailed epilepsy evaluation, including 
genetic studies, was pursued. epilepsy expanded 
panel was then obtained, which showed a p.R217c 
heterozygous autosomal dominant pathogenic 
variant of the GABRB3 gene. His seizures remain 
difficult to control with standard anti-seizure drugs. 
Although his neuroimaging studies did not suggest 
any additional epilepsy risk, he is now undergoing 
further epilepsy surgery evaluations.
D I S C U S S I O N
chromosome 15q11-13 is a complex genetic locus 
that encloses three GABAA receptor subunit 
(GABR) genes, GABRB3, GABRA5, and GABRG3. 
GABRB3 gene encodes for a member of the ligand-
gated ionic channel protein, which is one of the 
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subunits of a multi-subunit chloride channel that 
serves as the receptor for GABA, a major inhibitory 
neurotransmitter of the mammalian central nervous 
system.5 Usually, both the wild-type and mutant 
β3 subunit-containing α1β3γ2 GABAA receptors 
are attributed to impaired intracellular β3 subunit 
processing. It is believed that the β3 subunit is 
expressed in various neuromodulatory circuits in 
the cerebral cortex, hippocampus, and thalamic 
reticular nucleus, where they mediate phasic and 
tonic inhibition.6 GABRB3 gene mutation disorders 
continue to constitute a diagnostic challenge given 
the wide spectrum of linked clinical features and 
associated syndromes.7–10
The relationship between GABRB3 mutations 
and traits of ASD has been studied in several 
systemic reviews, but results seem to be conflicting. 
Some studies have demonstrated that single-
nucleotide polymorphisms (SNPs) in GABRB3 
have a statistically significant predictor value for 
development of ASD.11–13 However, expression of 
GABRB3 in a cohort of patients with ASD seems 
to be aberrant. A recent meta-analysis by Noroozi 
et al,14 suggested that some GABRB3 variants are 
not associated with increased risk of ASD. In fact, 
there is some evidence that different SNPs of GABA 
receptor B3, A5, and G3 subunit genes located 
on chromosome 15q11-q13 are not associated 
with the development of ASD in different ethnic 
populations.15 Our first case testing showed a de 
novo pathological p.l3101 variant in the GABRB3 
gene. To our knowledge, this variant was never 
reported before in a cohort of patients with ASD 
and GABRB3 mutations.
The contribution of GABRB3 gene alterations to 
increased risk for febrile seizures in children is still 
not well understood. Across the spectrum of GeFS+, 
GABRB3 mutations were found in a small group of 
patients. Mutations in ScN1A or GABRG2 are better 
studied in GeFS+ cohort of patients.16 In a recent 
review by Møller et al,17 416 patients with febrile 
seizures and early life epileptic encephalopathy were 
screened, identifying 22 patients with heterozygous 
mutations in GABRB3, including three probands 
from multiplex families. At the severe end of the 
clinical spectrum, GABRB3 mutations are thought 
to be closely associated with early-onset epileptic 
encephalopathy, although ScN8A and cDKl5 
mutations are more prevalent.18 Some recent reports 
suggest GABRB3 is a potential etiological substrate 
for severe myoclonic epilepsy of infancy, also known 
as Dravet syndrome.19 Our reported second patient 
is thought to fit the diagnosis of GeFS+ as she 
continues to progress developmentally so far. Her 
overall clinical progress and good control of seizures 
with low-dose levetiracetam make the possibility of 
other epileptic encephalopathies less likely.
Whether there is a substantial correlation 
between alterations in the GABRB3 gene and lower 
seizure threshold is an actively debated topic in the 
era of epilepsy epigenetics. The spectrum of possibly 
linked epilepsy syndromes is expanding, from 
more benign syndromes like childhood absence 
epilepsy to epileptic spasms and lennox Gastaut 
syndrome. Recent studies suggested that impaired 
receptor localization to synapses is a common 
pathophysiological mechanism for GABRB3 
mutations, although the extent of impairment may be 
different among mutant subunits, leading to variable 
epilepsy-related phenotypes.20,21 GABRB3 mutations 
were also noted in children with unclassified epilepsy 
along with other genetic alterations after more 
utilization of epilepsy genetic panel testing. No 
specific seizure classification has been described, 
thus emphasizing the role of genetic heterogeneity. 
Whether GABRB3 mutations can result in more 
severe phenotype and refractory epilepsy is not yet 
known. Our third reported patient is running a super 
refractory epilepsy clinical course and is currently 
under evaluation for possible epilepsy surgery 
consideration. Our patient had non-convulsive status 
epilepticus upon presentation, which has not been 
reported in patients with GABRB3 alterations. A 
recent review of the genetics of pediatric intractable 
epilepsy did not consider GABRB3 among the 
genetic mutations which are known to be associated 
with difficult-to-treat epilepsy.22
C O N C LU S I O N
GABAA receptor β3 subunits are widely expressed 
in the developing brain. Mutations in GABRB3 
gene appear to have a wide spectrum of clinical 
implications. We believe our three reported cases 
will add to the available knowledge about variations 
across both genotype and phenotype spectrum. 
More reports of this type will ultimately improve 
our understanding of how these genetic alterations 
are being translated into clinical manifestations for a 
wide range of neurological disorders, particularly in 
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the era of improved access and evolution of available 
genetic testing techniques and the whole future of 
precision-based medical care.
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